Metamark signs potential $365M deal with J&J unit

Metamark Genetics has entered an agreement with Janssen Biotech, a unit of Johnson & Johnson ($JNJ), to identify and characterize proprietary cancer targets that play a causal role in promoting tumor progression and spread (prognosis determinants). Under the terms of the agreement, Metamark will receive an initial upfront payment as well as up to $365 million in milestones across multiple targets.

After the targets are selected, Janssen will receive a limited exclusive license and will be responsible for the discovery, development and commercialization of therapeutic inhibitors targeting the specific prognosis determinants.

Metamark's platform allows doctors to identify which early-stage cancers are metastatic, permitting them to determine personalized treatment plans for patients. The company was founded in 2007 and has a number of seasoned diagnostic veterans on its management team, including CEO Mark Straley, whose background includes stints at J&J, Bayer Healthcare and Abbott Laboratories ($ABT).

"Our ultimate mission at Metamark Genetics is to improve cancer patient outcomes by empowering personalized treatment decisions," Straley said in a statement. "This collaboration advances our mission by enabling us to apply our unique understanding of tumor biology to direct the discovery and development of tumor-specific drugs and compounds."

- see the Metamark statement

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.